Adlai nortye ltd ANL.US 總覽分析
ANL 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
ANL 近期報酬表現
-0.52%
Adlai nortye ltd
2.16%
同產業平均
0.70%
S&P500
與 ANL 同產業的標的表現
- TEM Tempus ai inc價值 -趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
ANL 公司資訊
Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company's subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.